Can ICER Put a Value on Diabetes Management?

October 5, 2019

A new report from the Institute for Clinical and Economic Review says oral semaglutide treatment for people with Type 2 diabetes isn’t cost effective. But the report undervalues several key factors.

View the Graphic

Categorized in: Analysis

◀ Next Post

Previous Post ►